Cloudbreak Pharma Inc. (HKG:2592)

Revenue by Segment

Financials in millions USD. Fiscal year is January - December.

Fiscal Year	FY 2024	FY 2023	FY 2022
Period Ending	Dec 31, 2024	Dec 31, 2023	Dec 31, 2022
Research and Developments of Therapeutic Biologics	10.21M	880.00K	471.00K
Research and Developments of Therapeutic Biologics Growth	1060.68%	86.84%	-
Total	10.21M	880.00K	471.00K
Total Growth	1060.68%	86.84%	-

Source: S&P Global Market Intelligence.